subscribe
 

First hybrid drug-eluting stent

10th October 2014


BIOTRONIK’s Orsiro is the first hybrid Drug-Eluting Stent (DES) combining an active BIOlute coating and a passive proBIO coating. The release comes after a succession of studies demonstrating Orsiro's safety and efficiency in the treatment of discrete de-novo stenotic lesions and in-stent restenotic lesions.

Two high profile studies, BIOFLOW-II and BIOFLOW-III, showed Orsiro performing as best in class. BIOFLOW-II was a prospective, international, multi-centre, randomised trial evaluating the safety and efficacy of Orsiro compared with Xience Prime. 

The BIOFLOW-II and -III subgroup analyses released this year demonstrated the top performance of Orsiro in the treatment of patients with small vessel disease and complex B2/C lesions, respectively. The results of the much larger investigator-initiated BIOSCIENCE trial, which compared Orsiro with Xience Prime in a larger patient population more reflective of routine clinical practice, have further confirmed the ultra-thin Orsiro as best in class. The BIOSCIENCE results were published in the prestigious general medical journal The Lancet.

Based on the PRO-Kinetic Energy platform, Orsiro offers exceptional flexibility without compromising scaffolding or fatigue resistance, while a thinner 60µm strut design ensures minimal vessel injury. The stent will be offered in up to 40mm lengths, making it one of the longest drug-eluting stents on the market. Its design allows for stent expansion without affecting the performance of the polymer coating, ensuring improved patient outcome when treating coronary artery stenosis, even in patients with particularly long lesions.





Subscribe

Subscribe



Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe